Tag Archives: AML

Acute myeloid leukemia (AML) is most common in older adults. However, it is rarely cured by standard chemotherapy alone in older patients. According to NCI, it is critical that complete remission occurs, or there is no survival benefit. There are many clinically active therapies, including epigenetic drugs. A big translational research goal is to develop effective therapeutic strategies to demonstrate how and when oncologists should use these therapies.  A clinical combinational treatment regime could be guided in part by genome-wide methylation profiling. Genes in CpG islands and their promoters have established aberrant methylation patterns in cancers.  Perhaps also genome-wide methylation will help reveal new mechanistic details leading to new drug discoveries. Reduced representation bisulfite sequencing (RRBS) was introduced by scientists … Continue reading

Posted in Biomarkers, Clinical Studies, DNA Methylation, Genomewide Methylation Profiling, Leukemia, Next Gen Sequencing, Oncology, Reduced representation bisulfite sequencing | Tagged , , , , , | Leave a comment

According to NCI, there are well over 300 ongoing clinical trials for acute myeloid leukemia (AML). AML is an important disease model to our understanding of how epigenetics fits into the multidimensional cancer process.  Please find below a description of AML, and a few recent important studies providing traction on AML sub-type biomarkers and drug targets using epigenetic techniques. AML is a blood and marrow cancer. Myeloid stem cells abnormally propagate and differentiate into non-functional red blood cell, white blood cell, or platelets.  Clinical sub-typing is currently based on the degree of derivation from normal cells microscopically, and by cytogenic methods. Adult AML is diagnosed when 20% or greater leukemia cells appear in the bone marrow. Keep in mind, this … Continue reading

Posted in Applications, siRNA | Tagged , , , | 2 Comments